Emerging drugs for dementia with Lewy Bodies: a review of Phase II & III trials

Drug Discovery and Development Targeting Dementia

(2023) Agnieszka Zagórska et al.   Pharmaceuticals

Assessment of heterogeneity among participants in the Parkinson's Progression Markers Initiative cohort using α-synuclein seed amplification: a cross-sectional study

(2023) Andrew Siderowf et al.   LANCET NEUROLOGY

Systematic review of pharmacological interventions for people with Lewy body dementia

(2022) Katrina E. Watts et al.   AGING & MENTAL HEALTH

Synuclein-One study: skin biopsy detection of phosphorylated α-synuclein for diagnosis of synucleinopathies

(2022) Christopher H Gibbons et al.   Biomarkers in Medicine

Epidemiology and economic burden of Lewy body dementia in the United States

(2022) Urvi Desai et al.   CURRENT MEDICAL RESEARCH AND OPINION

Current Therapies and Drug Development Pipeline in Lewy Body Dementia: An Update

(2022) Steve MacDonald et al.   DRUGS & AGING

Phase 1 Single Ascending and Multiple Ascending Dose Studies of Phosphodiesterase-9 Inhibitor E2027

(2022) Ishani S. Landry et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

A Narrative Review of Studies Comparing Efficacy and Safety of Citalopram with Atypical Antipsychotics for Agitation in Behavioral and Psychological Symptoms of Dementia (BPSD)

(2022) Haider Saddam Qasim et al.   Pharmacy

Preclinical and randomized clinical evaluation of the p38α kinase inhibitor neflamapimod for basal forebrain cholinergic degeneration

(2022) Ying Jiang et al.   Nature Communications

Treatment needs of dementia with Lewy bodies according to patients, caregivers, and physicians: a cross-sectional, observational, questionnaire-based study in Japan

(2022) Mamoru Hashimoto et al.   Alzheimers Research & Therapy

RENEWAL: REpurposing study to find NEW compounds with Activity for Lewy body dementia—an international Delphi consensus

(2022) John T. O’Brien et al.   Alzheimers Research & Therapy

Preclinical and clinical biomarker studies of CT1812: A novel approach to Alzheimer's disease modification

(2021) Nicholas J. Izzo et al.   Alzheimers & Dementia

Association of Glycolysis-Enhancing α-1 Blockers With Risk of Developing Parkinson Disease

(2021) Jacob E. Simmering et al.   JAMA Neurology

Long-term Effects of Cholinesterase Inhibitors on Cognitive Decline and Mortality

(2021) Hong Xu et al.   NEUROLOGY

Nelotanserin as symptomatic treatment for rapid eye movement sleep behavior disorder: a double-blind randomized study using video analysis in patients with dementia with Lewy bodies or Parkinson's disease dementia

(2021) Ambra Stefani et al.   SLEEP MEDICINE

Outcome Measures for Dementia With Lewy Body Clinical Trials

(2021) Bhavana Patel et al.   ALZHEIMER DISEASE & ASSOCIATED DISORDERS

A phase 2 double-blind placebo-controlled 24-week treatment clinical study of the p38 alpha kinase inhibitor neflamapimod in mild Alzheimer’s disease

(2021) Niels D. Prins et al.   Alzheimers Research & Therapy

Impact of Behavioral and Psychological Symptoms on Caregiver Burden in Patients With Dementia With Lewy Bodies

(2021) Hideki Kanemoto et al.   Frontiers in Psychiatry

Alpha-synuclein fragments trigger distinct aggregation pathways

(2020) Tasnim Chakroun et al.   Cell Death & Disease

Ambroxol for the Treatment of Patients With Parkinson Disease With and Without Glucocerebrosidase Gene Mutations

(2020) Stephen Mullin et al.   JAMA Neurology

Plasma and Serum Alpha-Synuclein as a Biomarker of Diagnosis in Patients With Parkinson's Disease

(2020) Chun-Wei Chang et al.   Frontiers in Neurology

Clinical trials in REM sleep behavioural disorder: challenges and opportunities

(2020) Aleksandar Videnovic et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Cognitive decline profiles differ in Parkinson disease dementia and dementia with Lewy bodies

(2020) Denis S. Smirnov et al.   NEUROLOGY

Research criteria for the diagnosis of prodromal dementia with Lewy bodies

(2020) Ian G. McKeith et al.   NEUROLOGY

Role of Alterations in Protein Kinase p38γ in the Pathogenesis of the Synaptic Pathology in Dementia With Lewy Bodies and α-Synuclein Transgenic Models

(2020) Michiyo Iba et al.   Frontiers in Neuroscience

Involvement of p38 MAPK in Synaptic Function and Dysfunction

(2020) Chiara Falcicchia et al.   INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES

Continuous administration of a p38α inhibitor during the subacute phase after transient ischemia-induced stroke in the rat promotes dose-dependent functional recovery accompanied by increase in brain BDNF protein level

(2020) John J. Alam et al.   PLoS One

The usual suspects, dopamine and alpha-synuclein, conspire to cause neurodegeneration

(2019) Danielle E. Mor et al.   MOVEMENT DISORDERS

Multikinase Abl/DDR/Src Inhibition Produces Optimal Effects for Tyrosine Kinase Inhibition in Neurodegeneration

(2019) Alan J. Fowler et al.   Drugs in research & development

Clinical Presentation, Diagnostic Features, and Mortality in Dementia with Lewy Bodies

(2019) Sinéad Moylett et al.   JOURNAL OF ALZHEIMERS DISEASE

Pharmacological Management of Dementia with Lewy Bodies

(2019) Linda A. Hershey et al.   DRUGS & AGING

Dementia with Lewy bodies: Challenges in the diagnosis and management

(2019) Kai Sin Chin et al.   AUSTRALIAN AND NEW ZEALAND JOURNAL OF PSYCHIATRY

Survival time and differences between dementia with Lewy bodies and Alzheimer’s disease following diagnosis: A meta-analysis of longitudinal studies

(2019) Christoph Mueller et al.   AGEING RESEARCH REVIEWS

The costs of dementia subtypes to California Medicare fee-for-service, 2015

(2019) Yingjia Chen et al.   Alzheimers & Dementia

Alpha-synuclein structure and Parkinson’s disease – lessons and emerging principles

(2019) Richard M. Meade et al.   Molecular Neurodegeneration

Autophagy in Synucleinopathy: The Overwhelmed and Defective Machinery

(2019) Marie-Laure Arotcarena et al.   Cells

A comparison of the prevalence of orthostatic hypotension between older patients with Alzheimer's Disease, Lewy body dementia, and without dementia

(2019) Ahmet Turan Isik et al.   EXPERIMENTAL GERONTOLOGY

Enhancing glycolysis attenuates Parkinson’s disease progression in models and clinical databases

(2019) Rong Cai et al.   JOURNAL OF CLINICAL INVESTIGATION

New evidence on the management of Lewy body dementia

(2019) John-Paul Taylor et al.   LANCET NEUROLOGY

Ambroxol Hydrochloride Improves Motor Functions and Extends Survival in a Mouse Model of Familial Amyotrophic Lateral Sclerosis

(2019) Alexandra Bouscary et al.   Frontiers in Pharmacology

Clinical drug development for dementia with Lewy bodies: past and present

(2019) Garam Lee et al.   EXPERT OPINION ON INVESTIGATIONAL DRUGS

Plasma pS129-α-Synuclein Is a Surrogate Biofluid Marker of Motor Severity and Progression in Parkinson’s Disease

(2019) Lin et al.   Journal of Clinical Medicine

Effect of zonisamide on parkinsonism in patients with dementia with Lewy bodies: A phase 3 randomized clinical trial

(2019) Miho Murata et al.   PARKINSONISM & RELATED DISORDERS

Are dementia with Lewy bodies and Parkinson’s disease dementia the same disease?

(2018) Kurt A. Jellinger et al.   BMC Medicine

Cellular milieu imparts distinct pathological α-synuclein strains in α-synucleinopathies

(2018) Chao Peng et al.   NATURE

Adjunct zonisamide to levodopa for DLB parkinsonism

(2018) Miho Murata et al.   NEUROLOGY

Mirabegron in patients with Parkinson disease and overactive bladder symptoms: A retrospective cohort

(2018) Benoit Peyronnet et al.   PARKINSONISM & RELATED DISORDERS

An exploratory clinical study of p38α kinase inhibition in Alzheimer's disease

(2018) Philip Scheltens et al.   Annals of Clinical and Translational Neurology

Cholinesterase inhibitors and memantine for Parkinson's disease dementia and Lewy body dementia: A meta‑analysis

(2018) Yan‑Hong Meng et al.   Experimental and Therapeutic Medicine

Caregiver burden, sleep quality, depression, and anxiety in dementia caregivers: a comparison of frontotemporal lobar degeneration, dementia with Lewy bodies, and Alzheimer's disease

(2017) Shuai Liu et al.   INTERNATIONAL PSYCHOGERIATRICS

Systematic review of the efficacy of non-pharmacological interventions in people with Lewy body dementia

(2017) Hamilton Morrin et al.   INTERNATIONAL PSYCHOGERIATRICS

Long-Term Cognitive Decline in Dementia with Lewy Bodies in a Large Multicenter, International Cohort

(2017) Milica G. Kramberger et al.   JOURNAL OF ALZHEIMERS DISEASE

Dementia with Lewy bodies and Parkinson’s disease-dementia: current concepts and controversies

(2017) Kurt A. Jellinger   JOURNAL OF NEURAL TRANSMISSION

Accuracy of clinical diagnosis of dementia with Lewy bodies: a systematic review and meta-analysis

(2017) Giovanni Rizzo et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Neuropathological and genetic correlates of survival and dementia onset in synucleinopathies: a retrospective analysis

(2017) David J Irwin et al.   LANCET NEUROLOGY

Author response: Autopsy validation of 123 I-FP-CIT dopaminergic neuroimaging for the diagnosis of DLB

(2017) Alan J. Thomas et al.   NEUROLOGY

Diagnosis and management of dementia with Lewy bodies

(2017) Ian G. McKeith et al.   NEUROLOGY

Long-term cognitive outcome of Alzheimer’s disease and dementia with Lewy bodies: dual disease is worse

(2017) Frédéric Blanc et al.   Alzheimers Research & Therapy

Neuropathological Staging of Brain Pathology in Sporadic Parkinson’s disease: Separating the Wheat from the Chaff

(2017) Heiko Braak et al.   Journal of Parkinsons Disease

Ambroxol effects in glucocerebrosidase and α-synuclein transgenic mice

(2016) Anna Migdalska-Richards et al.   ANNALS OF NEUROLOGY

The Prevalence and Incidence of Dementia with Lewy Bodies: a Systematic Review

(2016) David B. Hogan et al.   CANADIAN JOURNAL OF NEUROLOGICAL SCIENCES

Caregiver burden in family carers of people with dementia with Lewy bodies and Alzheimer's disease

(2016) Ellen Svendsboe et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Different Clinical and Neuroimaging Characteristics in Early Stage Parkinson’s Disease with Dementia and Dementia with Lewy Bodies

(2016) Mami Takemoto et al.   JOURNAL OF ALZHEIMERS DISEASE

Activation of tyrosine kinase c-Abl contributes to α-synuclein–induced neurodegeneration

(2016) Saurav Brahmachari et al.   JOURNAL OF CLINICAL INVESTIGATION

Concomitant AD pathology affects clinical manifestation and survival in dementia with Lewy bodies

(2016) A W Lemstra et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Arguing against the proposed definition changes of PD

(2016) Bradley F. Boeve et al.   MOVEMENT DISORDERS

BMS-708163 and Nilotinib restore synaptic dysfunction in human embryonic stem cell-derived Alzheimer’s disease models

(2016) Hisae Nishioka et al.   Scientific Reports

Nilotinib Effects in Parkinson’s disease and Dementia with Lewy bodies

(2016) Fernando Pagan et al.   Journal of Parkinsons Disease

Amyloid-β 1–24 C-terminal truncated fragment promotes amyloid-β 1–42 aggregate formation in the healthy brain

(2016) Sonia Mazzitelli et al.   Acta Neuropathologica Communications

Selective loss of glucocerebrosidase activity in sporadic Parkinson’s disease and dementia with Lewy bodies

(2015) Davide Chiasserini et al.   Molecular Neurodegeneration

Two sides of the same coin: tyrosine kinase inhibition in cancer and neurodegeneration

(2015) Charbel E-H Moussa et al.   Neural Regeneration Research

Cortical Lewy bodies and Aβ burden are associated with prevalence and timing of dementia in Lewy body diseases

(2015) C. Ruffmann et al.   NEUROPATHOLOGY AND APPLIED NEUROBIOLOGY

Structural characterization of toxic oligomers that are kinetically trapped during α-synuclein fibril formation

(2015) Serene W. Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Melatonin therapy for REM sleep behavior disorder: a critical review of evidence

(2015) Ian R. McGrane et al.   SLEEP MEDICINE

Comprehensive treatment of dementia with Lewy bodies

(2015) Brendon P Boot   Alzheimers Research & Therapy

Long-term Safety of Rivastigmine in Parkinson Disease Dementia

(2014) Murat Emre et al.   CLINICAL NEUROPHARMACOLOGY

c-Abl phosphorylates α-synuclein and regulates its degradation: implication for α-synuclein clearance and contribution to the pathogenesis of Parkinson's disease

(2014) Anne-Laure Mahul-Mellier et al.   HUMAN MOLECULAR GENETICS

Memantine improves attention and episodic memory in Parkinson's disease dementia and dementia with Lewy bodies

(2014) Keith A. Wesnes et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY

Efficacy and safety of cholinesterase inhibitors and memantine in cognitive impairment in Parkinson's disease, Parkinson's disease dementia, and dementia with Lewy bodies: systematic review with meta-analysis and trial sequential analysis

(2014) H.-F. Wang et al.   JOURNAL OF NEUROLOGY NEUROSURGERY AND PSYCHIATRY

Terazosin activates Pgk1 and Hsp90 to promote stress resistance

(2014) Xinping Chen et al.   Nature Chemical Biology

The clinical characteristics of dementia with Lewy bodies and a consideration of prodromal diagnosis

(2014) Paul C Donaghy et al.   Alzheimers Research & Therapy

Nilotinib reverses loss of dopamine neurons and improves motor behavior via autophagic degradation of  -synuclein in Parkinson's disease models

(2013) M. L. Hebron et al.   HUMAN MOLECULAR GENETICS

Incidence of Dementia With Lewy Bodies and Parkinson Disease Dementia

(2013) Rodolfo Savica et al.   JAMA Neurology

Ambroxol as a pharmacological chaperone for mutant glucocerebrosidase

(2012) Inna Bendikov-Bar et al.   BLOOD CELLS MOLECULES AND DISEASES

Examining carer stress in dementia: the role of subtype diagnosis and neuropsychiatric symptoms

(2012) David R Lee et al.   INTERNATIONAL JOURNAL OF GERIATRIC PSYCHIATRY